Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the succe ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

TNF Pharmaceuticals, Inc. ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced ...

The report by GlobalData, a data and analytics company, showed that anti-obesity medications are the industry trend that will ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...